TScan Therapeutics (TCRX) Operating Margin Growth (3y) (2023 - 2026)

TScan Therapeutics (TCRX) Operating Margin Growth (3y) (2023 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Operating Margin Growth (3y) (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 9,942.00
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 530.00
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn -1,211.00
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -623.00
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 TScan Therapeutics 100.59 Mn -27.47 Mn - -257,519.00

Historic Data

Download Data
DateValue
Mar 31, 2026 -257,519.00
Dec 31, 2025 -32,686.00
Sep 30, 2025 -98,263.00
Jun 30, 2025 -88,071.00
Mar 31, 2025 -113,472.00
Dec 31, 2024 -502,298.00
Sep 30, 2024 -245,302.00
Jun 30, 2024 -598,959.00
Mar 31, 2024 -515,231.00
Dec 31, 2023 68,622.00
Sep 30, 2023 183,607.00